Literature DB >> 11160861

Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.

S G Shiah1, S E Chuang, M L Kuo.   

Abstract

Paclitaxel is a novel anticancer drug that has demonstrated efficacy toward treating several malignant tumor types. Here, we demonstrate that c-Jun NH(2)-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2, was persistently activated by paclitaxel or other microtubule-damaging agents within human leukemia HL-60 cells. Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis. Furthermore, we found that the full-length MEKK1 was cleaved to a 91-kDa carboxyl-terminal fragment at the earlier time of apoptosis induced by microtubule-damaging agents. This cleavage, however, occurred consistently with JNK activation and Bcl-2 phosphorylation, but preceded DNA fragmentation in cells in response to paclitaxel activity. The caspase inhibitor Ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO), but not Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO), effectively blocked MEKK1 cleavage, JNK activation, Bcl-2 phosphorylation, and subsequent apoptosis. Subcellular fractionation revealed that the 91-kDa C-terminal MEKK1 fragment was translocated to cytosol. Notably, the MEKK1 fragment could be coimmunoprecipitated with anti-JNK antibodies, suggesting that a signaling complex of C-terminal MEKK1/stress-activated protein kinase/extracellular-signal regulated kinase 1/JNK formed during apoptosis induced by microtubule-damaging agents. Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160861     DOI: 10.1124/mol.59.2.254

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

1.  Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Authors:  Yintao Ye; Wenqing Xu; Wei Zhong; Yajing Li; Chen Wang
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

2.  A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.

Authors:  Margarette Bryan; E Dianne Pulte; Kathleen C Toomey; Lillian Pliner; Anna C Pavlick; Tracie Saunders; Robert Wieder
Journal:  Invest New Drugs       Date:  2010-07-02       Impact factor: 3.850

3.  MEKK1 is essential for DT40 cell apoptosis in response to microtubule disruption.

Authors:  R Kwan; J Burnside; T Kurosaki; G Cheng
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

4.  Regulation of apoptosis by Caspases under oxidative stress conditions in mice testicular cells: in vitro molecular mechanism.

Authors:  Sumiti Kalia; M P Bansal
Journal:  Mol Cell Biochem       Date:  2008-11-01       Impact factor: 3.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.